SUPNSupernus Pharmaceuticals, Inc.

$3B

Q3 2017 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$80M+41.5% YoY

Gross Profit

$76M94.7% margin

Operating Income

$22M27.8% margin

Net Income

$16M19.9% margin

EPS (Diluted)

$0.29

QoQ Revenue Growth

+6.0%

Cash Flow

Operating Cash Flow

$39M

Free Cash Flow

$39M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$385M

Total Liabilities

$134M

Stockholders' Equity

$252M

Cash & Equivalents

$82M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$80M	$57M	+41.5%
Gross Profit	$76M	$53M	+42.6%
Operating Income	$22M	$20M	+12.6%
Net Income	$16M	$62M	-74.2%

SUPN Q3 2017 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena